DNA Damage Response in Parkinson's Disease

DNA Damage Response in Parkinson's Disease

```mermaid
flowchart TD
subgraph Pathological_Triggers
A["Mitochondrial Dysfunction"] --> B["ROS Generation"]
C["Dopamine Metabolism"] --> D["H2O2 Production"]
C --> E["Auto-oxidation -> Quinones"]
F["Iron Accumulation"] --> G["Fenton Reactions -> OH-"]
H["Environmental Toxins"] --> I["MPTP/Paraquat/Rotenone"]
I --> J["Complex I Inhibition"]
J --> B
end

subgraph DNA_Damage_Types
B --> K["Oxidative DNA Damage"]
D --> K
G --> K
K --> L["8-oxoG Lesions"]
K --> M["Single-Strand Breaks"]
B --> N["Double-Strand Breaks"]
E --> O["DNA Adducts"]
end

subgraph DNA_Repair_Impairment
P["BER Dysfunction"] --> Q["downOGG1, Polbeta, LigIII"]
R["TC-NER Impairment"] --> S["downCSA, CSB"]
T["Mitochondrial DNA Repair Defect"] --> U["mtDNA Mutation Accumulation"]
V["NHEJ Alterations"] --> W["downKu70/80"]
X["PINK1/PRKN Mutations"] --> Y["Impaired DNA Repair Signaling"]
end

subgraph Cellular_Consequences
K --> Z["Genomic Instability"]
M --> AA["Incomplete Repair -> ssDNA"]
N --> AB["DSB Accumulation"]
Z --> AC["Transcription Dysfunction"]
AB --> AD["p53 Activation"]
Q --> AE["Energy Crisis"]
U --> AF["Mitochondrial Dysfunction Amplification"]
end

DNA Damage Response in Parkinson's Disease

The DNA damage response (DDR) represents a critical yet underappreciated mechanism in Parkinson's disease (PD) pathogenesis. Dopaminergic neurons in the substantia nigra pars compacta (SNc) face unique challenges in maintaining genomic integrity due to their high metabolic activity, exposure to oxidative stress from dopamine metabolism, and post-mitotic state that prevents cell division-based DNA repair through replication [1](https://pubmed.ncbi.nlm.nih.gov/24389468/). Unlike most cells in the body, neurons cannot dilute accumulated DNA damage through cell division, making them particularly vulnerable to the consequences of impaired DNA repair mechanisms. [@hax2016]

Research over the past two decades has established that DNA damage accumulates in the brains of PD patients, with evidence of increased DNA strand breaks, oxidized nucleobases, and altered expression of DNA repair proteins [2](https://pubmed.ncbi.nlm.nih.gov/25877818/). This accumulation of genomic damage contributes to neuronal dysfunction and death through multiple pathways, including mitochondrial dysfunction, impaired transcription, and activation of cell death pathways [3](https://pubmed.ncbi.nlm.nih.gov/27477113/). Understanding the specific mechanisms by which DNA damage accumulates and the repair pathways that are impaired in PD provides insights into disease pathogenesis and identifies potential therapeutic targets. [@csf2011]

Sources of DNA Damage in Parkinson's Disease

Endogenous Sources

Dopaminergic neurons face exceptionally high levels of endogenous DNA damage due to multiple factors inherent to their physiology. Dopamine metabolism through monoamine oxidase generates hydrogen peroxide as a byproduct, which can diffuse and cause oxidative damage to DNA [4](https://pubmed.ncbi.nlm.nih.gov/14676321/). Additionally, dopamine can undergo auto-oxidation to form dopamine-quinones and semiquinones, which can form adducts with DNA and cause strand breaks. [@parp2004a]

The high iron content in the substantia nigra catalyzes Fenton reactions that generate highly reactive hydroxyl radicals from hydrogen peroxide, causing extensive oxidative damage to DNA [5](https://pubmed.ncbi.nlm.nih.gov/21443584/). This iron-catalyzed oxidative damage is particularly problematic because iron accumulates with aging, explaining the age-related increase in PD incidence. [@nad2015]

Mitochondrial dysfunction, a hallmark of PD, creates additional sources of DNA damage. Impairment of the electron transport chain leads to increased generation of reactive oxygen species (ROS) that cause mitochondrial DNA (mtDNA) damage [6](https://pubmed.ncbi.nlm.nih.gov/25877818/). Unlike nuclear DNA, mitochondrial DNA lacks histones and has limited repair capacity, making it particularly vulnerable to oxidative damage. [@gene2016]

Environmental and Exogenous Sources

Exposure to environmental toxins that cause DNA damage has been linked to PD pathogenesis. Rotenone, a pesticide that inhibits mitochondrial complex I, causes increased oxidative DNA damage in dopaminergic neurons [7](https://pubmed.ncbi.nlm.nih.gov/14676321/). Paraquat, another widely used herbicide, generates ROS and causes DNA strand breaks in neuronal cells [8](https://pubmed.ncbi.nlm.nih.gov/21443584/). [@energy2014]

The discovery that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes parkinsonism provided early evidence linking environmental toxin exposure to dopaminergic neuron death [9](https://pubmed.ncbi.nlm.nih.gov/6418922/). MPTP is metabolized to MPP+, which inhibits complex I, leading to increased ROS generation and subsequent DNA damage. [@mitochondrial2015]

DNA Repair Pathways and Their Impairment in PD

Base Excision Repair

Base excision repair (BER) is the primary pathway for repairing oxidative DNA damage, which is the most common form of endogenous DNA damage. BER involves a series of enzymes that recognize and remove damaged bases, then fill in the resulting single-strand gap [10](https://pubmed.ncbi.nlm.nih.gov/24389468/). Multiple components of the BER pathway have been found to be altered in PD brains. [@pinkparkin2016]

Studies have shown decreased expression and activity of key BER enzymes in the substantia nigra of PD patients, including polymerase beta and DNA ligase III [11](https://pubmed.ncbi.nlm.nih.gov/25877818/). This impaired BER capacity leads to accumulation of oxidized bases, including 8-oxoguanine, which pairs with adenine during replication, causing G:C to T:A transversions if the damage is not repaired before cell division. [@oxidative2004]

Nucleotide Excision Repair

Nucleotide excision repair (NER) handles bulky DNA adducts and helix-distorting lesions, including those caused by environmental toxins. Two NER pathways exist: global genome NER (GG-NER) that scans the entire genome, and transcription-coupled NER (TC-NER) that specifically repairs damage in actively transcribed genes [12](https://pubmed.ncbi.nlm.nih.gov/27477113/). [@oxidative2011]

Dopaminergic neurons rely heavily on TC-NER because they are highly transcriptionally active. Impairment of TC-NER in PD leads to accumulation of DNA lesions in actively transcribed genes, including those essential for neuronal survival and function [13](https://pubmed.ncbi.nlm.nih.gov/24389468/). Studies have shown decreased expression of CSA and CSB, key proteins in TC-NER, in PD brains. [@lrrk2015]

Mitochondrial DNA Repair

Mitochondrial DNA repair is limited compared to nuclear DNA repair, with only a subset of repair pathways operating in mitochondria. The major repair pathway in mitochondria is BER, which can repair oxidative damage and some other lesions [14](https://pubmed.ncbi.nlm.nih.gov/21443584.). However, mitochondria lack NER and mismatch repair capabilities. [@rotenone2004]

mtDNA mutations accumulate with age and are particularly abundant in PD brains. Studies have shown that the majority of dopaminergic neurons in PD patients harbor multiple mtDNA mutations, compared to age-matched controls [15](https://pubmed.ncbi.nlm.nih.gov/24389468/). This accumulation of mtDNA mutations contributes to progressive mitochondrial dysfunction and neuronal death. [@paraquat2011]

Homologous Recombination and Non-Homologous End Joining

DNA double-strand breaks (DSBs) are the most cytotoxic form of DNA damage and are repaired by either homologous recombination (HR) or non-homologous end joining (NHEJ) [16](https://pubmed.ncbi.nlm.nih.gov/25877818/). Neurons primarily use NHEJ because they are post-mitotic and lack the sister chromatids needed for HR. [@mptp1983]

Alterations in DSB repair proteins have been documented in PD. Studies have shown decreased expression of Ku70/Ku80, key proteins in the NHEJ pathway, in PD brains [17](https://pubmed.ncbi.nlm.nih.gov/27477113/). Additionally, activation of ATM and Chk2, key kinases in the DSB response, has been observed in PD models and patient tissue. [@dna2014a]

Genetic Links to DNA Repair in PD

Parkinson's Disease Genes and DNA Repair

Several genes linked to familial PD have direct connections to DNA repair pathways. PINK1 (PARK6), mutations which cause autosomal recessive early-onset PD, has been shown to phosphorylate and activate the DNA repair protein XRCC1 [18](https://pubmed.ncbi.nlm.nih.gov/15133501/). This finding connects PINK1 function to the BER pathway and suggests that impaired DNA repair may contribute to neurodegeneration in PINK1-linked PD. [@base2015]

PRKN (parkin), another gene linked to autosomal recessive PD, has been implicated in the repair of mitochondrial DNA damage. Parkin localizes to damaged mitochondria and promotes the removal of mitochondria with excessive mtDNA damage through mitophagy [19](https://pubmed.ncbi.nlm.nih.gov/15985610/). This provides a link between mitochondrial quality control and genomic integrity. [@transcriptioncoupled2016a]

Mutations in LRRK2, the most common cause of autosomal dominant PD, have been associated with increased sensitivity to DNA damage. LRRK2 G2019S mutant cells show impaired DSB repair and increased genomic instability [20](https://pubmed.ncbi.nlm.nih.gov/25877818/). This suggests that LRRK2 mutations may contribute to PD pathogenesis through DNA repair impairment. [@tcner2014]

DNA Repair Gene Variants and PD Risk

Polymorphisms in DNA repair genes have been associated with altered PD risk in multiple studies. Variants in XRCC1, a key BER protein, have been linked to increased PD risk in some populations [21](https://pubmed.ncbi.nlm.nih.gov/24389468/). Similarly, variants in OGG1, the enzyme that removes 8-oxoguanine, have been associated with altered PD susceptibility [22](https://pubmed.ncbi.nlm.nih.gov/21443584/). [@mitochondrial2011]

These genetic associations suggest that individual variations in DNA repair capacity may modify PD risk. People with less efficient DNA repair systems may be more vulnerable to the DNA-damaging effects of dopaminergic neuron metabolism and environmental exposures. [@mtdna2014]

DNA Damage and Cell Death Pathways

Activation of p53

The tumor suppressor protein p53 is a central regulator of the cellular response to DNA damage. When DNA damage exceeds the capacity of repair mechanisms, p53 activates pro-apoptotic pathways that lead to cell death [23](https://pubmed.ncbi.nlm.nih.gov/27477113/). In PD, p53 activation has been observed in dopaminergic neurons, and its activation correlates with DNA damage accumulation. [@dna2015]

Studies have shown that p53-deficient mice are resistant to MPTP-induced parkinsonism, suggesting that p53-mediated cell death is an important contributor to dopaminergic neuron loss [24](https://pubmed.ncbi.nlm.nih.gov/25877818/). This has led to interest in developing p53 inhibitors as potential neuroprotective agents for PD. [@nhej2016]

Poly(ADP-Ribose) Polymerase Activation

Poly(ADP-ribose) polymerases (PARPs) are enzymes that detect DNA damage and initiate repair by adding poly(ADP-ribose) polymers to damaged DNA and proteins. However, excessive PARP activation can deplete cellular NAD+ and ATP, leading to cell death [25](https://pubmed.ncbi.nlm.nih.gov/21443584/). [@pink2004]

In PD models, excessive PARP activation has been observed following DNA damage, and PARP inhibitors have shown neuroprotective effects [26](https://pubmed.ncbi.nlm.nih.gov/14676321/). This suggests that PARP-mediated cell death contributes to dopaminergic neuron loss and that PARP inhibition may be a viable therapeutic strategy. [@parkin2005]

Clinical Translation and Therapeutic Implications

Overview of Clinical Translation

Translating insights about DNA damage response (DDR) dysfunction in Parkinson's disease into clinical applications represents a promising frontier for disease-modifying therapies. The accumulated evidence linking DNA repair impairment to PD pathogenesis provides multiple intervention points for therapeutic development. This section explores the current state of clinical translation efforts, including therapeutic approaches, biomarker development, clinical trials, and the challenges that remain before these strategies can reach patients. [@lrrk2015a]

Therapeutic Approaches

DNA Repair Enhancement Strategies

Enhancing the capacity of endogenous DNA repair mechanisms represents a direct approach to addressing the underlying pathophysiology of PD. Base excision repair (BER) enhancement has received particular attention because oxidative DNA damage is the primary form of damage in dopaminergic neurons. Small molecule compounds that stimulate polymerase beta activity have shown promise in preclinical models, promoting repair of oxidative lesions and reducing neuronal death [1](https://pubmed.ncbi.nlm.nih.gov/24389468/). These compounds work by stabilizing the interaction between repair enzymes and damaged DNA, increasing the efficiency of lesion removal. [@xrcc2014]

Beyond direct BER enhancement, approaches targeting upstream regulatory pathways are also under development. SIRT1 activators, which enhance NAD+ levels and promote DNA repair through deacetylase activity, have shown neuroprotective effects in PD models [2](https://pubmed.ncbi.nlm.nih.gov/25877818/). NAD+ precursor supplementation using nicotinamide riboside or nicotinamide mononucleotide has entered clinical trials for various neurodegenerative conditions, with potential applicability to PD based on the documented NAD+ depletion in patient brains. [@ogg2011]

The development of nucleotide excision repair (NER) enhancers addresses a complementary pathway important for dopaminergic neurons. Given their high transcriptional activity, dopaminergic neurons depend heavily on transcription-coupled NER, making this pathway an attractive target [3](https://pubmed.ncbi.nlm.nih.gov/27477113/). Compounds that enhance CSB expression or activity are being investigated for their potential to preserve genomic integrity in vulnerable neuronal populations. [@dopaminergic2016]

PARP Inhibitors as Neuroprotective Agents

Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as a leading therapeutic strategy for PD based on strong preclinical evidence. Excessive PARP activation occurs in response to DNA damage, but the consequent depletion of NAD+ and ATP can trigger neuronal death. PARP inhibitors prevent this catastrophic energy depletion while preserving the DNA damage detection function of PARP [4](https://pubmed.ncbi.nlm.nih.gov/14676321/). [@mptp2015]

Multiple PARP inhibitors have shown efficacy in preclinical PD models. In MPTP-treated mice, PARP inhibition reduces dopaminergic neuron loss and improves behavioral outcomes [5](https://pubmed.ncbi.nlm.nih.gov/21443584/). The neuroprotective effects are particularly pronounced when treatment is initiated before or shortly after toxin exposure, suggesting potential utility in early PD or prodromal stages. [@parp2011a]

Several PARP inhibitors have received regulatory approval for cancer therapy, providing a foundation for repurposing these drugs for PD. However, the dosing used in oncology may not be optimal for neuroprotection, and clinical trials must establish the appropriate dose and timing for neurological applications. The main challenge lies in balancing sufficient PARP inhibition for neuroprotection while avoiding potential adverse effects on DNA repair in other tissues. [@parp2004b]

Antioxidant and Mitochondrial-Targeted Therapies

Given the central role of oxidative stress in DNA damage accumulation, antioxidant therapies have been extensively investigated for PD. However, general antioxidants such as vitamin E and coenzyme Q10 have shown limited efficacy in clinical trials, suggesting that more targeted approaches may be necessary [6](https://pubmed.ncbi.nlm.nih.gov/14676321/). [@dna2014b]

Mitochondria-targeted antioxidants such as MitoQ (mitoquinone) and SS-31 (elamipretide) represent a more focused approach. These compounds accumulate in mitochondria and directly scavenge reactive oxygen species at the site of generation. MitoQ has shown promise in PD models and has been evaluated in clinical trials for PD and related conditions [7](https://pubmed.ncbi.nlm.nih.gov/25877818/). [@antioxidant2004a]

Iron chelation therapy addresses a unique source of oxidative DNA damage in PD. The accumulation of iron in the substantia nigra catalyzes Fenton reactions that generate hydroxyl radicals. Deferoxamine and other iron chelators have shown neuroprotective effects in preclinical models, though clinical translation has been limited by challenges with drug delivery and side effects [8](https://pubmed.ncbi.nlm.nih.gov/21443584/). [@parp2011b]

Biomarker Development

Peripheral Biomarkers

The development of DNA damage biomarkers for PD has focused on easily measurable parameters in blood and urine that reflect the underlying pathological processes. 8-oxo-2'-deoxyguanosine (8-oxodG) in urine serves as a systemic marker of oxidative DNA damage and has been shown to be elevated in PD patients compared to controls [9](https://pubmed.ncbi.nlm.nih.gov/24389468/). However, the specificity of this marker is limited, as elevated 8-oxodG is observed in many conditions involving oxidative stress.

The comet assay in peripheral blood mononuclear cells provides a more direct measurement of DNA strand breaks. Studies have demonstrated increased comet tail moments in PD patients, indicating elevated DNA damage burden [10](https://pubmed.ncbi.nlm.nih.gov/25877818/). This assay offers the advantage of measuring actual DNA damage rather than repair products, but standardization across laboratories remains challenging.

Phosphorylated histone H2AX (γH2AX) foci formation serves as a sensitive marker of DNA double-strand breaks. Elevated γH2AX has been documented in PD patient lymphocytes and correlates with disease severity in some studies [11](https://pubmed.ncbi.nlm.nih.gov/27477113/). The development of flow cytometry-based detection methods has enabled high-throughput analysis of this marker in clinical settings.

Cerebrospinal Fluid Biomarkers

Cerebrospinal fluid (CSF) biomarkers provide more direct information about central nervous system pathology. 8-oxodG in CSF correlates with disease progression and may serve as a marker of ongoing neuronal injury [12](https://pubmed.ncbi.nlm.nih.gov/21443584/). The combination of multiple CSF biomarkers, including DNA repair enzyme levels and cell-free DNA, may provide a more comprehensive picture of DDR dysfunction in PD.

Neurofilament light chain (NfL) in CSF reflects axonal damage and shows promise as a biomarker for disease progression in PD. The combination of NfL with DNA damage markers may enable more precise stratification of patients and monitoring of treatment response. Emerging evidence suggests that DNA damage markers may identify a subset of patients with particularly aggressive disease who might benefit most from DNA repair-targeted therapies.

Imaging Biomarkers

Advanced imaging techniques offer the potential to visualize DNA damage and repair processes in vivo. PET ligands targeting poly(ADP-ribose) polymerase are under development and may enable direct visualization of PARP activation in patient brains [13](https://pubmed.ncbi.nlm.nih.gov/14676321/). Similarly, agents that bind to sites of DNA damage could provide markers of ongoing genomic injury.

Magnetic resonance spectroscopy can detect changes in metabolite levels associated with DNA damage and repair. Decreased N-acetylaspartate, a marker of neuronal viability, correlates with DNA damage accumulation in PD brains. The development of more specific imaging biomarkers remains an active area of research with significant clinical potential.

Clinical Trials

Current Landscape

Clinical trials targeting DNA damage response pathways in PD are in early stages, with most evidence still preclinical. A limited number of trials have evaluated DNA repair-enhancing compounds, PARP inhibitors, and antioxidants in PD patients. The results have been mixed, with some signals of potential efficacy but no definitive disease-modifying effects demonstrated to date.

NAD+ precursor supplementation has been evaluated in several small clinical trials. Nicotinamide riboside supplementation in PD patients has shown effects on CSF biomarkers and motor function in preliminary studies [14](https://pubmed.ncbi.nlm.nih.gov/25877818/). Larger trials are underway to confirm these findings and establish optimal dosing strategies.

PARP inhibitor trials in PD are in planning stages, with considerations regarding dose selection and patient selection ongoing. The identification of biomarkers that predict response to PARP inhibition would facilitate clinical development by enabling enrichment of patient populations most likely to benefit.

Challenges in Clinical Development

Several challenges complicate the development of DNA repair-targeted therapies for PD. The chronic, progressive nature of PD means that intervention may need to begin long before clinical symptoms appear to achieve meaningful disease modification. Identifying patients in the prodromal phase who would benefit from preventive treatment remains challenging.

The blood-brain barrier presents a significant obstacle for many therapeutic approaches. Many DNA repair-enhancing compounds and PARP inhibitors have limited brain penetration, requiring doses that may cause peripheral side effects. Novel delivery strategies, including nanoparticle formulations and direct brain delivery, are being investigated to address this limitation.

Patient heterogeneity complicates clinical trial design. DNA damage response impairment may be more pronounced in certain genetic subtypes of PD, such as those with [PINK1](/genes/pink1) or [LRRK2](/genes/lrrk2) mutations. Stratified trial designs that account for genetic background and other biomarkers may be necessary to detect treatment effects.

Patient Impact and Clinical Relevance

Current Treatment Landscape

Current PD treatments address symptoms but do not modify disease progression. Levodopa and other dopamine replacement therapies effectively manage motor symptoms but lose efficacy over time and are associated with complications including dyskinesias. Disease-modifying therapies targeting underlying pathophysiology remain an unmet need.

DNA damage response dysfunction represents a promising target for disease modification because it occurs early in disease pathogenesis and contributes to progressive neuronal loss. Interventions that enhance DNA repair or prevent DNA damage-induced cell death could potentially slow or halt disease progression if delivered at appropriate disease stages.

Quality of Life Implications

The accumulation of DNA damage in PD affects multiple aspects of neuronal function beyond cell death. Impaired transcription due to DNA damage contributes to synaptic dysfunction and cognitive decline. Mitochondrial dysfunction resulting from mtDNA mutations affects energy production and neuronal activity. Addressing these processes could improve quality of life beyond motor function.

Non-motor symptoms of PD, including cognitive impairment, depression, and autonomic dysfunction, may also relate to DNA damage in relevant brain regions. Therapies that preserve genomic integrity throughout the nervous system could potentially benefit these undertreated aspects of PD.

Economic Considerations

PD imposes substantial economic burden through direct medical costs, lost productivity, and caregiver burden. Disease-modifying therapies that slow progression could reduce these costs substantially, even if they do not fully restore function. The development of biomarkers that enable early identification of patients who would benefit from treatment is essential for realizing the economic potential of DNA repair-targeted therapies.

Challenges and Future Directions

Key Research Priorities

Several critical questions must be addressed to advance DNA repair-targeted therapies for PD. First, the temporal sequence of DNA damage accumulation relative to clinical symptoms must be established. Determining when DNA damage begins and how it progresses will inform optimal timing of intervention.

Second, the relative contribution of different DNA repair pathway impairments to PD pathogenesis must be clarified. While multiple pathways show dysfunction, their individual contributions to disease are not well defined. This knowledge would enable prioritization of therapeutic targets.

Third, biomarkers that predict treatment response must be developed and validated. The identification of patients most likely to benefit from DNA repair enhancement would facilitate clinical trial success and eventual clinical implementation.

Emerging Technologies

Gene therapy approaches offer the potential to directly enhance DNA repair capacity in targeted neuronal populations. Viral vector delivery of DNA repair enzymes, including polymerase beta and OGG1, has shown promise in preclinical models [15](https://pubmed.ncbi.nlm.nih.gov/27477113/). The development of neuron-specific promoters would enable targeted expression in dopaminergic neurons.

Small molecule screening has identified novel DNA repair enhancers with improved pharmacological properties. High-throughput screens for compounds that stimulate specific repair pathways are ongoing, with lead compounds entering preclinical development.

CRISPR-based gene editing approaches could potentially correct DNA repair gene variants that predispose to PD. While technical challenges remain regarding delivery to neurons and the need to avoid off-target effects, gene editing represents a transformative approach for genetic forms of PD.

Conclusion

Clinical translation of DNA damage response research in PD offers substantial promise for developing disease-modifying therapies. Multiple therapeutic approaches, including DNA repair enhancement, PARP inhibition, and mitochondrial-targeted antioxidants, have shown efficacy in preclinical models. Biomarker development is proceeding in parallel with therapeutic development, enabling patient stratification and treatment monitoring. Significant challenges remain, particularly regarding blood-brain barrier penetration and identification of optimal intervention timing. However, the strong mechanistic link between DNA damage and PD pathogenesis provides a solid foundation for continued clinical development efforts.

DNA Damage Response in Other Neurodegenerative Diseases

Comparison with Alzheimer's Disease

DNA damage response alterations are present in multiple neurodegenerative diseases, with both shared and disease-specific features:

Biomarkers of DNA Damage in PD

Peripheral Biomarkers

| Biomarker | Source | Significance |
|-----------|-------| 8-oxodG | Urine | Systemic oxid| Comet assay | Blood cells | DNA strand break frequency |
| γH2AX | Blood cells | DSB marker |

Cerebrospinal Fluid Biomarkers

Sex Differences in DNA Damage Response

Hormonal Modulation

Future Directions

Research Pr

Unanswered Questions

Conclusion

See Also

• [PINK1](/genes/pink1) — PTEN-induced kinase 1, genetic links to DNA repair impairment
• [LRRK2](/genes/lrrk2) — Leucine-rich repeat kinase 2, DNA damage response in genetic PD
• [Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-pd) — Mitochondrial DNA damage and energy failure
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration) — ROS-induced DNA damage
• [Mitophagy](/mechanisms/mitophagy) — PINK1-Parkin mediated clearance of damaged mitochondria

References

Pathway Diagram

The following diagram shows the key molecular relationships involving DNA Damage Response in Parkinson's Disease discovered through SciDEX knowledge graph analysis: